Abstract

BackgroundBreast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, is highly overexpressed and activated in basal-like breast cancer.MethodsTo understand the role of FAK in this subtype, we generated mice with conditional deletion of FAK and a knock-in mutation in its kinase domain in MMTV-Wnt1-driven basal-like mammary tumors. Tumor initiation, growth, and metastasis were characterized for these mice cohorts. Immunohistochemical and transcriptomic analysis of Wnt1-driven tumors were also performed to elucidate the mechanisms underlying FAK-dependent phenotypes. Pharmacological inhibition of FAK and mTOR in human basal-like breast cancer cell lines was also tested.ResultsWe found that in the absence of FAK or its kinase function, growth and metastasis of the tumors were significantly suppressed. Furthermore, immunohistochemical analyses of cleaved caspase 3 revealed that loss of FAK results in increased tumor cell apoptosis. To further investigate the mechanism by which FAK regulates survival of the Wnt1-driven tumor cells, we prepared an isogenic pair of mammary tumor cells with and without FAK and found that FAK ablation increased their sensitivity to ER stress-induced cell death, as well as reduced tumor cell migration and tumor sphere formation. Comparative transcriptomic profiling of the pair of tumor cells and gene set enrichment analysis suggested mTOR pathway to be downregulated upon loss of FAK. Immunoblot analyses further confirmed that absence of FAK results in reduction of AKT and downstream mTOR pathways. We also found that inhibition of FAK and mTOR pathways both induces apoptosis, indicating the importance of these pathways in regulating cell survival.ConclusionsIn summary, our studies show that in a basal-like tumor model, FAK is required for survival of the tumor cells and can serve as a potential therapeutic target.

Highlights

  • Our studies show that in a basal-like mammary tumor model, focal adhesion kinase (FAK) is required for survival of the tumor cells and could potentially serve as a therapeutic target in the treatment of basal-like breast cancer

  • Elevated FAK expression is associated with worse patient prognosis and is more prevalent in basal-like breast cancers To establish potential associations corresponding to the expression of FAK in human breast cancers, we queried the METABRIC dataset [32] that includes a large patient cohort (2509 tumors) through cBioPortal [33] and found that FAK gene (Official Symbol: PTK2) was amplified in 415 (21%) of these tumors

  • Three cohorts of female mice with the genotypes FAK floxed allele (FAKfl)/fl, mammary tumor virus (MMTV)-Cre, and MMTV-Wnt1; FAKfl/KD, MMTV-Cre, and MMTV-Wnt1; and FAKfl/KD and MMTV-Wnt1, along with FAKfl/fl and MMTVWnt1 were established. These mice were examined for the appearance of tumors, in order to gauge the importance of FAK and its kinase activity for mammary tumor development and progression

Read more

Summary

Introduction

Breast cancer is a heterogeneous disease and transcriptome profiling has led to the identification of at least six molecular subtypes of the disease, including luminal A, luminal B, Her2-enriched, basal-like, claudinlow, and normal-like [1]. Each of these subtypes is associated with varying prognoses and has differential sensitivities to conventional therapies. The basal and claudin-low subtypes are known to have poorest outcomes in patients as compared to the other subtypes but do not respond to hormonal or HER2-targeted therapy [2] This highlights the necessity of finding novel treatment strategies to target basal-like breast cancers, since effective treatment options are still lacking

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call